These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9573106)

  • 1. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.
    Wessels MR; Paoletti LC; Guttormsen HK; Michon F; D'Ambra AJ; Kasper DL
    Infect Immun; 1998 May; 66(5):2186-92. PubMed ID: 9573106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
    Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC; Paoletti LC; Tai JY; Kasper DL
    J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
    Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
    Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
    Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
    Paoletti LC; Kasper DL; Michon F; DiFabio J; Holme K; Jennings HJ; Wessels MR
    J Biol Chem; 1990 Oct; 265(30):18278-83. PubMed ID: 2120228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
    Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
    J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
    Paoletti LC; Kennedy RC; Chanh TC; Kasper DL
    Infect Immun; 1996 Feb; 64(2):677-9. PubMed ID: 8550227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Pinel J; Kasper DL
    J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
    Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
    Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
    Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
    Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
    Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths.
    Rana R; Dalal J; Singh D; Kumar N; Hanif S; Joshi N; Chhikara MK
    Vaccine; 2015 May; 33(23):2646-54. PubMed ID: 25907408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.
    Lagergard T; Shiloach J; Robbins JB; Schneerson R
    Infect Immun; 1990 Mar; 58(3):687-94. PubMed ID: 2407652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.